Douglas Blayney is an Oncology physician affiliated with Stanford Medicine. OpenAlex indexes 333 publications with 15,388 citations (h-index 55); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
Sponsor: BeyondSpring Pharmaceuticals Inc.
- Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
Sponsor: BeyondSpring Pharmaceuticals Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Similar KOLs
Other experts from the same institution or the same specialty.
Jeffrey Teuteberg, MD
Stanford Medicine
Charles Debattista, MD
Stanford Medicine
Michael Amylon, MD
Stanford Medicine
Kimberly Dequattro, MD, MM
Stanford Medicine
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”